Status:
COMPLETED
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
a 48-week, 2-arm parallel group, "fixed combination" beclomethasone dipropionate plus formoterol fumarate versus formoterol in patients with severe chronic obstructive pulmonary disease
Detailed Description
a 48-week, double blind, randomized, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" beclomethasone dipropionate plus formoterol ...
Eligibility Criteria
Inclusion
- Severe COPD
- At least one COPd exacerbation in previous year
Exclusion
- Asthma, allergic rhinitis or other atopic disease
- Unstable concurrent disease:
- Evidence of heart failure
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
1199 Patients enrolled
Trial Details
Trial ID
NCT00929851
Start Date
October 1 2009
End Date
July 1 2012
Last Update
October 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCL Medical School
London, United Kingdom